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Abstract
Aims/hypothesis Progressive decline in functional beta cell mass is central to the development of type 2 diabetes. Elevated serum
levels of extracellular nicotinamide phosphoribosyltransferase (eNAMPT) are associated with beta cell failure in type 2 diabetes
and eNAMPT immuno-neutralisation improves glucose tolerance in mouse models of diabetes. Despite this, the effects of
eNAMPT on functional beta cell mass are poorly elucidated, with some studies having separately reported beta cell-protective
effects of eNAMPT. eNAMPT exists in structurally and functionally distinct monomeric and dimeric forms. Dimerisation is
essential for the NAD-biosynthetic capacity of NAMPT. Monomeric eNAMPT does not possess NAD-biosynthetic capacity and
may exert distinct NAD-independent effects. This study aimed to fully characterise the structure-functional effects of eNAMPT
on pancreatic beta cell functional mass and to relate these to beta cell failure in type 2 diabetes.
Methods CD-1mice and serum from obese humans who were without diabetes, with impaired fasting glucose (IFG) or with type
2 diabetes (from the Body Fat, Surgery and Hormone [BodyFatS&H] study) or with or at risk of developing type 2 diabetes (from
the VaSera trial) were used in this study. We generated recombinant wild-type and monomeric eNAMPT to explore the effects of
eNAMPT on functional beta cell mass in isolated mouse and human islets. Beta cell function was determined by static and
dynamic insulin secretion and intracellular calcium microfluorimetry. NAD-biosynthetic capacity of eNAMPTwas assessed by
colorimetric and fluorescent assays and by native mass spectrometry. Islet cell number was determined by immunohistochemical
staining for insulin, glucagon and somatostatin, with islet apoptosis determined by caspase 3/7 activity. Markers of inflammation
and beta cell identity were determined by quantitative reverse transcription PCR. Total, monomeric and dimeric eNAMPT and
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nicotinamide mononucleotide (NMN) were evaluated by ELISA, western blot and fluorometric assay using serum from non-
diabetic, glucose intolerant and type 2 diabetic individuals.
Results eNAMPT exerts bimodal and concentration- and structure-functional-dependent effects on beta cell functional mass. At
low physiological concentrations (~1 ng/ml), as seen in serum from humans without diabetes, eNAMPT enhances beta cell
function through NAD-dependent mechanisms, consistent with eNAMPT being present as a dimer. However, as eNAMPT
concentrations rise to ~5 ng/ml, as in type 2 diabetes, eNAMPT begins to adopt a monomeric form and mediates beta cell
dysfunction, reduced beta cell identity and number, increased alpha cell number and increased apoptosis, through NAD-
independent proinflammatory mechanisms.
Conclusions/interpretation We have characterised a novel mechanism of beta cell dysfunction in type 2 diabetes. At low
physiological levels, eNAMPT exists in dimer form and maintains beta cell function and identity through NAD-dependent
mechanisms. However, as eNAMPT levels rise, as in type 2 diabetes, structure-functional changes occur resulting in marked
elevation of monomeric eNAMPT, which induces a diabetic phenotype in pancreatic islets. Strategies to selectively target
monomeric eNAMPT could represent promising therapeutic strategies for the treatment of type 2 diabetes.
Keywords Beta cell . eNAMPT . Extracellular nicotinamide phosphoribosyltransferase . Inflammation . Insulin secretion .
NAD . Type 2 diabetes
Abbreviations
AMP-CP Adenosine 5′-(α,β-methylene)diphosphate
eNAMPT Extracellular nicotinamide
phosphoribosyltransferase
eNAMPT-WT Recombinant wild-type extracellular
nicotinamide phosphoribosyltransferase
FPG Fasting plasma glucose
GSIS Glucose-stimulated insulin secretion
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IFG Impaired fasting glucose
iNAMPT Intracellular nicotinamide
phosphoribosyltransferase
JNK c-Jun N-terminal kinase
MAPK Mitogen-activated protein kinase
NAMPT Nicotinamide phosphoribosyltransferase
NMN Nicotinamide mononucleotide
STAT3 Signal transducer and activator of
transcription 3
WT Wild-type
Introduction
Elucidating the underlying mechanisms responsible for progres-
sive decline in functional beta cell mass is essential for the design
of novel treatments for type 2 diabetes [1]. The protein nicotin-
amide phosphoribosyltransferase (NAMPT) exists in intracellu-
lar (iNAMPT) and extracellular (eNAMPT) forms. eNAMPT
(also known as visfatin/pre-B cell enhancing factor [PBEF]) is
a circulating protein with several reported functions [2–4].
Similar to iNAMPT, eNAMPT may exert NAD-biosynthetic
effects, whereby eNAMPT catalyses the conversion of nicotin-
amide to nicotinamide mononucleotide (NMN) in serum [5, 6].
NMN may subsequently be transported into the cell (directly or
via conversion into nicotinamide riboside), where it is converted
into NAD by nicotinamide mononucleotide adenylyltransferases
(NMNATs) 1–3. However, this mechanism has been disputed
and NAD-independent functions, including eNAMPT-mediated
proinflammatory effects, are also reported [4, 7–9].
Serum eNAMPT levels are elevated in type 2 diabetes, in
association with declining beta cell function. Our in vivo studies
indicate that eNAMPT may mediate type 2 diabetes pathophysi-
ology [10–12]. Contrasting studies report that eNAMPT and its
reaction product NMN exert beta cell-protective effects by
boosting cellular NAD levels [6, 13–19].
A key, but frequently overlooked factor governing eNAMPT
function is the presence of structurally and functionally distinct
monomeric (~52 KDa) and dimeric (~104 KDa) eNAMPT.
Dimerisation is essential for NAD-biosynthetic capacity of
eNAMPT [6, 20] and the eNAMPT dimer predominates in
normal physiology [12, 15]. The eNAMPT monomer does not
possess NAD-biosynthetic capacity and may mediate NAD-
independent proinflammatory effects. Our studies
suggested a specific pathophysiological role for monomer-
ic eNAMPT in mouse models of diabetes [12]. We
hypothesised that, in type 2 diabetes, eNAMPT monomer
is selectively elevated, which exerts NAD-independent
proinflammatory effects, and that this, combined with the
loss of eNAMPT’s NAD-biosynthetic capacity, plays a key
role in disease pathophysiology.
However, whether eNAMPT monomer is elevated in type 2
diabetes and to what extent the structurally distinct forms of
eNAMPT directly affect the pancreatic beta cell are unknown.
Previous studies, including our own, have examined NAD-
boosting effects of NMNon beta cell function [6, 13, 14], or have
examined supraphysiological concentrations or acute effects of
eNAMPT [21, 22], neither of which accurately mimic in vivo
(patho)physiology. Of perhaps greater importance, the selective
effects of monomeric and dimeric eNAMPT on beta cell health
have not been examined.
We used isolated mouse and human islets, and serum from
humans with type 2 diabetes, to specifically characterise the
effects of monomeric and dimeric eNAMPT on pancreatic beta
cell functional mass.
Methods
Animals Eight-week-old male CD-1 mice (28–33 g; Envigo,
Blackthorn, UK) were housed in 12 h light/dark cycle,
temperature-controlled conditions with ad libitum access to stan-
dard mouse chow (Envigo) and water. Procedures were
performed in accordance with UK Home Office regulations
(Animal Scientific Procedures Act, 1986).
Human samples Human serum was obtained from obese indi-
viduals without diabetes, (BMI >30 kg/m2; fasting plasma
glucose [FPG] <5.6 mmol/l; n= 13 individuals), with impaired
fasting glucose (IFG; BMI >30 kg/m2; FPG 5.6–6.9 mmol/l; n=
15 individuals)) or with type 2 diabetes (BMI >30 kg/m2; FPG
>7.0mmol/l; n= 27 individuals), as part of the Body Fat, Surgery
and Hormone (BodyFatS&H) study (University of Auckland,
Auckland, New Zealand) and from obese individuals with or at
risk of developing type 2 diabetes as part of the VaSera trial (St
Thomas’ Hospital, London) [23, 24]. Study participants gave
informed consent. Investigations were approved by the
Northern Regional Ethics Committee (NREC), Auckland, New
Zealand (BodyFatS&H) and the National Research Ethics
Service (NRES) Committee, London Central (VaSera). See elec-
tronic supplementary material (ESM)Methods for further details.
Native mass spectrometry Native mass spectrometry was
conducted using the Synapt G2S high definition mass spectrom-
eter (HDMS; Waters, Manchester, UK) (see ESM Methods).
eNAMPT protein generation Recombinant wild-type (WT)
eNAMPT (eNAMPT-WT) and mutant SS199/200DD
(eNAMPT monomer) were produced in Escherichia coli.
See ESM Methods for details.
Pancreatic islet isolation Mouse islets were isolated between
9:00 and 10:00 hours [25]. Human islets were isolated from
heart-beating non-diabetic donors, with ethical approval, at the
King’s College Hospital Human Islet Isolation Unit (London,
UK) [25] (see ESM Human Islets Checklist for further details).
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All isolated islets were incubated overnight (37°C, 5%CO2) prior
to treatments (ESM Methods). RPMI media was used for all
incubations. Islets were size-matched prior to treatments. Mouse
and human islets were treated with eNAMPT (WTor monomer;
0.1–5 ng/ml) or NMN (100 μmol/l) for 24, 48 or 72 h. For
inflammatory pathway inhibition, mouse islets were incubated
with 1 ng/ml eNAMPT monomer or 5 ng/ml eNAMPT-WT, in
combination with inhibitors of signal transducer and activator of
transcription 3 (STAT3; using NCS74859; 50 μmol/l), P38-
mitogen-activated protein kinase (MAPK; using SB203580;
1 μmol/l), NF-κB (using BAY 11-7082; 1 μmol/l) or c-Jun N-
terminal kinase (JNK; using SP600125; 50 μmol/l), (Tocris
Biosciences, Abingdon, UK). For CD73 inhibition, mouse islets
were incubated with 0.5–5 ng/ml eNAMPT-WT for 48 h in
combination with adenosine 5′-(α,β-methylene)diphosphate
(AMP-CP; 1 μmol/l; Sigma-Aldrich, Poole, UK)
Static and dynamic glucose-stimulated insulin secretion
Static or dynamic insulin secretion was assessed in response
to 2 mmol/l or 20 mmol/l glucose exposure, as previously
described [25]. Secreted insulin was measured by in-house
125I radioimmunoassay [26] (see ESM Methods).
Endotoxin measurement Endotoxin concentrations were
measured in recombinant eNAMPT preparations using the
Pierce LAL Chromogenic Endotoxin Quantitation Kit
(ThermoFisher Scientific, Altrincham, UK).
In vitro islet immunostaining Mouse islets were pelleted and
fixed in 4% (vol./vol.) buffered formalin. Sections (5 μmol/l)
were incubated with anti-guinea pig insulin (Dako, Stockport,
UK; catalogue no. A0564), anti-rabbit glucagon (Abcam,
Cambridge, UK; ab92517) or anti-rat somatostatin (Abcam;
ab30788) (1:100 for all; K) and DAPI (ThermoFisher).
Secondary antibodies used were AlexaFluor 488-labelled
donkey anti-rat (712-545-1250), AlexaFluor 594-labelled
donkey anti-guinea pig (06-585-148) and AlexaFluor 488-
labelled donkey anti-rabbit (711-545-152) (1:200 for all;
Jackson ImmunoResearch, Cambridge UK). Sections were
mounted on glass slides and captured on a Nikon TE2000
fluorescent microscope (Nikon Instruments, Melville, NY,
USA) and quantified using ImageJ (https://imagej.nih.gov/ij/
download.html; accessed December 2017–June 2018).
Islet apoptosisMouse islets were treated with eNAMPTwith or
without cytokine cocktail (0.05 U/μl IL-1β, 1 U/μl TNF-α and
1 U/μl IFNγ; 48 h). Apoptosis was determined by the Caspase-
Glo 3/7 luminescent assay (Promega, Southampton, UK).
Quantitative reverse transcription PCR Gene expression was
determined by SYBR Green quantitative reverse transcription
PCR using ΔΔCt methodology and normalised against glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH)
(QuantiTect; Qiagen, Manchester, UK). See ESM Methods
and ESM Table 1.
Intracellular calciumWhole mouse islets, incubated in HEPES
bicarbonate buffer (containing 2–20 mmol/l glucose), were
loaded with Fura-2 AM and imaged using a Nikon Ti-E
microscope equipped with FuraLEDs (Cairn Research,
Faversham, UK) (excitation, 340/385 nm; emission, 470–
550 nm).
MIN6 cell culture MIN6 cells (mycoplasma free; obtained
from J. I. Miyazaki, Osaka University, Osaka, Japan [27,
28]) were cultured at 37°C in DMEM (25 mmol/l glucose;
2 mmol/l glutamine, 10% FBS (vol./vol.), 100 U/ml penicil-
lin, 100 μg/ml streptomycin) and treated with eNAMPT (1–
5 ng/ml WT; 1 ng/ml monomer) or NMN (100 μmol/l) (48 h;
Sigma-Aldrich), prior to NAD and NMN measurements.
eNAMPT, NAD and NMN measurements Total serum
eNAMPT was measured by ELISA (Adipogen, Seoul, South
Korea). MIN6 intracellular NAD and NMN levels were
measured by an NAD/NADH Quantification Kit, (Sigma-
Aldrich) and an in-house fluorometric assay, respectively
[29, 30] (see ESM Methods).
eNAMPT Immunoblotting Serum eNAMPT monomer and
dimer were measured by immunoblotting, under non-
reducing conditions, as previously described [31]. To ensure
equivalent loading of each lane, serum protein was normalised
to 10 μg and an equal volume (30 μl) was added to each well
(see ESM Methods).
Data analysis Data are expressed as mean ± SEM.
Significance was tested using one- or two-way ANOVAwith
Tukey’s or Sidak’s post hoc test, using GraphPad PRISM 7
software (San Diego, CA, USA). Experimenters were not
blind to group assignment and outcome assessment.
Results
Serum eNAMPTmonomer concentrations are elevated in type
2 diabetes and are positively correlated with increased HbA1c
We first demonstrated that serum eNAMPT concentrations
increased with progression of type 2 diabetes (Fig. 1a): in
obese non-diabetic individuals, serum eNAMPT concentra-
tions were 1.7 ± 0.4 ng/ml, rising to 3.4 ± 0.7 ng/ml in indi-
viduals with IFG and 4.6 ± 0.6 ng/ml in type 2 diabetes (p <
0.05 vs non-diabetic for both IFG and type 2 diabetes). These
concentrations are similar to those observed in previous stud-
ies [32–34]. Increasing eNAMPT concentrations strongly
correlated (r2 = 0.3787; p < 0.01) with increasing HbA1c
(mmol/mol), indicating a role of eNAMPT in mediating poor
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glycaemic control (Fig. 1b). Next, we specifically measured
serum eNAMPT monomer and dimer by immunoblotting
under non-reducing conditions. eNAMPT monomer was
almost absent in serum from individuals without diabetes,
but increased markedly in type 2 diabetes. Specifically, in
individuals without diabetes, serum eNAMPT was 95.8%
dimer and 4.2%monomer. However, in type 2 diabetes, serum
eNAMPTwas 71% dimer and 29% monomer, which translat-
ed into a mean concentration of 1.83 ng/ml eNAMPT mono-
mer (Fig. 1c–e). Increasing eNAMPT concentrations did not
correlate with serum NMN levels and NMN was not associ-
ated with HbA1c (Fig. 1f, g). This suggests a selective patho-
physiological role for eNAMPT monomer in type 2 diabetes.
Neither eNAMPT nor NMN correlated with BMI, age or
serum insulin (ESM Fig. 1).
eNAMPT exerts bimodal effects on beta cell function in
mouse and human pancreatic islets Increased HbA1c is indic-
ative of poor glycaemic control and deteriorating beta cell
function. To assess the (patho)physiological effects of
eNAMPT on beta cells, we used serum eNAMPT concentra-
tions (as detected in Fig. 1a and [12]) and exposed isolated
islets to physiological (1 ng/ml) and pathophysiological
(5 ng/ml) eNAMPT. To account for batch-to-batch differences
between commercially available eNAMPT [8], we generated
recombinant wild-type eNAMPT (eNAMPT-WT). To specif-
ically examine eNAMPT monomer, we mutated Ser199/200
(key residues in the NAMPT binding interface [6, 20]) to
aspartic acid. This generated a 52 KDa protein (eNAMPT
monomer), which neither dimerised correctly, as demonstrat-
ed by size-exclusion chromatography and native MS, nor
synthesised cellular NMN and NAD (ESM Fig. 2a–e).
Neither eNAMPT-WT nor eNAMPT monomer contained
notable endotoxin concentrations (ESM Fig. 2f)
eNAMPT-WT induced a bimodal response; 1 ng/ml
eNAMPT significantly enhanced static glucose-stimulated
insulin secretion (GSIS) in mouse and human islets (24–
48 h; Fig. 2a, b, e, f), and enhanced dynamic GSIS (48 h;
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Fig. 1 Serum eNAMPT levels are increased in type 2 diabetes and are
associated with increased HbA1c. Serum was collected from obese indi-
viduals without diabetes (non-diabetic [ND]), with IFG and with type 2
diabetes (T2D), and eNAMPTwas measured by ELISA or immunoblot.
(a) Serum eNAMPT (data generated from BodyFatS&H and VaSera trial
samples); (b) Serum eNAMPT vs HbA1c (data generated from VaSera
trial only). (c–e) Western blot of serum eNAMPTmonomer and dimer (c)
and quantification of percentage ratio of eNAMPTmonomer and dimer in
serum from non-diabetic and type 2 diabetic individuals (d) and concen-
tration of eNAMPT monomer and dimer in serum from individuals with
type 2 diabetes only (e). In (c–e): n = 4; data generated from
BodyFatS&H and VaSera trial samples. (f) Serum NMN and (g) serum
NMN vs HbA1c (data generated from VaSera trial only). n values differ
for NMNmeasurements due to limited availability of some samples. Data
are expressed as means ± SEM. *p < 0.05, **p < 0.01, by one-way
ANOVAwith Tukey’s post hoc test, or Pearson correlation
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Fig. 2h, i) and intracellular cytosolic calcium levels ([Ca2+]cyt)
(Fig. 2l, m; AUC, p < 0.01) in mouse islets. In contrast, neither
5 ng/ml eNAMPT-WT nor eNAMPTmonomer (0.1–5 ng/ml;
48 h) stimulated static or dynamic GSIS or increased
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Fig. 2 GSIS has a bimodal response to eNAMPT. (a–d) Static insulin
secretion in response to basal (2 mmol/l) or 20 mmol/l glucose was
assessed in isolated mouse islets incubated with 1 or 5 ng/ml eNAMPT-
WT for (a) 24 h and (b) 48 h, or with 0.1, 1 or 5 ng/ml eNAMPT
monomer for (c) 24 h and (d) 48 h. (e) Static insulin secretion in response
to 20mmol/l glucose was assessed in isolated mouse islets incubated with
1 or 5 ng/ml eNAMPT-WT and eNAMPT monomer. (f, g) Static insulin
secretion in response to basal (2 mmol/l) or 20 mmol/l glucose was
assessed in isolated human islets incubated with (f) 1 or 5 ng/ml
eNAMPT-WT or (g) 0.1, 1 or 5 ng/ml eNAMPT monomer for 48 h.
For (a–g): black bars, 2 mmol/l glucose; grey bars, 20 mmol/l glucose.
n = 5–28, where an n of 1 equals five islets per incubation tube, repeated
8–10 times. (h–k) Dynamic insulin secretion was assessed in isolated
mouse islets incubated with (h, i) 1 or 5 ng/ml eNAMPT-WT or (j, k)
with 1 or 5 ng/ml eNAMPT monomer for 48 h by perifusion with
2 mmol/l glucose (2G) or with 20 mmol/l glucose (20G) with or without
20 mmol/l KCl. n = 9–12, where an n of 1 equals one perifusion of 160
islets isolated from 4–6 mice. (l, m) Glucose-stimulated [Ca2+]cyt was
measured in isolated mouse islets treated with 1 or 5 ng/ml eNAMPT-
WT for 48 h (n = 9–16 islets/treatment from three mice). Calcium data are
expressed as F/F minimum, where F is fluorescence at any given time
point and F minimum is the minimum fluorescence during the recording.
For (h–m): black, 0 ng/ml eNAMPT; blue, 1 ng/ml eNAMPT-WT; grey,
5 ng/ml eNAMPT-WT. (n) Static insulin secretion in response to basal
(2 mmol/l) or 20 mmol/l glucose was assessed in isolated mouse islets
incubated with 1 ng/ml eNAMPT-WT ± 1 ng/ml eNAMPT monomer for
48 h (n = 4–19). Black bars, 2 mmol/l glucose; grey bars, 20 mmol/l
glucose. Data are expressed as means ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001, as indicated. In (e): ***p < 0.001 vs 1 ng/ml eNAMPT-
WT; †††p < 0.001 vs 0 ng/ml eNAMPT-WT; ‡p < 0.05, ‡‡p < 0.01 vs
0 ng/ml eNAMPT monomer. In (h) and (j): *p < 0.05, **p < 0.01,
***p < 0.001, 0 ng/ml vs 1 ng/ml eNAMPT; †p < 0.05, ††p < 0.01, 1 ng/ml
vs 5 ng/ml eNAMPT. Data analysed by two-way ANOVAwith Tukey’s
post hoc test (a–g, n) or one-way ANOVAwith Bonferroni’s post hoc test
(h–m)
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intracellular calcium in mouse or human islets, with similar or
reduced levels of these variables compared with islets not
treated with eNAMPT (Fig. 2a–m). A similar bimodal
insulin-secretory response was observed following exposure
to commercial eNAMPT (Adipogen, Seoul, South Korea;
ESM Fig. 3a-c).
We also assessed effects of a combination of eNAMPT-WT
and eNAMPTmonomer, which is more representative of normal
(patho)physiology. eNAMPT-WT (1 ng/ml) alone induced GSIS
as expected; however, when eNAMPT-WT (1 ng/ml) was added
in combination with eNAMPTmonomer, the insulin stimulatory
effects of eNAMPT-WTwere lost (Fig. 2n).
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Fig. 3 Pathophysiological eNAMPT mediates reductions in beta cell
identity and number. (a–c) Gene expression of Nkx2-2, Nkx6-1, Pdx1
and Ins2 was measured in mouse islets treated with (a, b) 1 ng/ml
eNAMPT-WT (blue bars), 5 ng/ml eNAMPT-WT (grey bars), or (c)
1 ng/ml eNAMPT monomer (grey bars) for 48 h. In (a–c), black bars,
untreated. (d) Apoptosis (caspase 3/7 activity) was measured in islets
treated with eNAMPT-WT with (grey bars) and without (black bars) a
cocktail of cytokines (TNF-α, IFNγ and IL-1β; n = 7–16, where an n of 1
equals one well with six size-matched islets); (e–k) Mouse islets were
treated with 1 or 5 ng/ml eNAMPT-WT for 48 h and assessed by immu-
nofluorescence. (e) Double immunofluorescence images of islets stained
for insulin (green) and DAPI (blue) and (f) bar chart showing per cent of
insulin+/DAPI cells. (g) Double immunofluorescence images of islets
stained for glucagon (red) and DAPI (blue) and (h) bar chart showing
per cent of glucagon+/DAPI stained cells. (i) Immunofluorescence images
of islets stained for insulin (green), glucagon (red) and DAPI (blue) and
(j) bar chart showing per cent DAPI/glucagon+:DAPI/insulin+ cells. (k)
Per cent of insulin+/glucagon+ bi-hormonal cells. For (e–k), n = 3, where
n of 1 equals 200–300 islets from 1mouse. Data are expressed as means ±
SEM. *p < 0.05, **p < 0.01, ***p < 0.001, by two-way ANOVA with
Tukey’s post hoc test (a, b, d) or one-way ANOVA with Bonferroni’s
post hoc test (c, f, h, j, k)
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Together this demonstrates that low, physiological levels of
eNAMPTenhance beta cell function, but as eNAMPT rises to
pathophysiological levels (~5 ng/ml), beneficial effects are
lost and eNAMPT mediates beta cell dysfunction. The effects
of high concentrations of eNAMPT-WTare mimicked by non-
dimerising eNAMPT monomer, consistent with the notion
that eNAMPT-WT adopts monomeric structure and function
at higher concentrations.
Pathophysiological eNAMPT reduces beta cell number and
identity and increases alpha cell number Type 2 diabetes is
characterised by reduced beta cell mass, with loss of beta cell
identity and increased apoptosis as possible mechanisms.
Consistent with the bimodal insulin-secretory response,
mRNA levels of islet Ins2 (p > 0.05) and the essential beta cell
identity markers [35] Pdx1 (p < 0.01), Nkx2-2 (p < 0.01) and
Nkx6-1 (p < 0.05) were increased in mouse islets by 1 ng/ml
eNAMPT-WT but not by 5 ng/ml eNAMPT-WT, nor 1 ng/ml
eNAMPT monomer (48 h; Fig. 3a–c), as compared with
untreated islets. Treatment with 5 ng/ml eNAMPT-WT also
enhanced cytokine-mediated islet apoptosis, (caspase 3/7
activity) (p < 0.001 vs no eNAMPT; Fig. 3d), as well as signif-
icantly reducing insulin+ cells (p < 0.05) and increasing gluca-
gon+ cells (p < 0.05) and non-significantly increasing somato-
statin+ cells, denoting decreased beta cell and increased alpha
and delta cell number, respectively (Fig. 3e–k; ESM Fig. 4).
eNAMPT impairs beta cell function via proinflammatory
mechanisms Proinflammatory effects of eNAMPT are report-
ed, although, to date, not in type 2 diabetes. eNAMPT-WT at
5 ng/ml (48 h), but not at 1 ng/ml, increased mouse islet Il1b
(p < 0.05) and Ccl2 (p < 0.001) gene expression, as compared
with untreated islets (Fig. 4a). Similarly, eNAMPT monomer
(1 ng/ml; 48 h) increased IL1B/Il1b and CCL2/Ccl2 gene
expression in mouse and human islets (significant [p < 0.05]
for Il1b only) (Fig. 4b). Inflammatory pathway inhibitors
demonstrated that inhibition of STAT3 and P38-MAPK, but
not of NF-κB or JNK (inhibition of which still resulted in
reduced GSIS; p > 0.05 for NF-κB and p < 0.05 for JNK),
blocked the inhibitory effects of eNAMPT on GSIS (Fig. 4c).
Therefore, pathophysiological concentrations of eNAMPT-
WT and eNAMPT monomer induce beta cell dysfunction, in
part through promotion of STAT3 and P38-mediated islet
inflammation.
Structure-functional changes mediate bimodal effects of
eNAMPT-WT Since the effects of eNAMPT monomer were
mimicked by 5 ng/ml, but not 1 ng/ml eNAMPT-WT, we
hypothesised that high concentrations of eNAMPT-WT
(5 ng/ml) would be associated with reduced NAD-
biosynthetic capacity (compared with 1 ng/ml eNAMPT-
WT), indicative of reduced eNAMPT dimer and increased
eNAMPT monomer levels.
In support of this, treatment of MIN6 cells with 1 ng/ml
eNAMPT-WT (48 h) increased cellular NMN (p < 0.05) and
NAD (p > 0.05) vs basal levels, by 30% and 20%, respective-
ly. These changes were mimicked by NMN treatment
(100 μmol/l for 48 h; Fig. 5a–d). NMN also mimicked the
functional effects of 1 ng/ml eNAMPT-WT, significantly
increasing levels of GSIS and Ins2, Nkx2-2 and Pdx1
mRNA (Fig. 5e, f). In contrast, and similar to the effects of
eNAMPT monomer, 5 ng/ml eNAMPT-WT did not increase
cellular NMN or NAD (Fig. 5a–d and ESM Fig. 2d-e).
Furthermore, AMP-CP-mediated inhibition of CD73 (a
protein involved in cellular NMN uptake) [36–40] inhibited
the insulin-secretory effects of 1 ng/ml eNAMPT-WT (p <
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Fig. 4 Monomeric eNAMPT impairs GSIS via proinflammatory mecha-
nisms. (a) Gene expression of Ccl2, Tnfa and Il1b in mouse islets after
treatment with eNAMPT-WTat 1 ng/ml (blue bars) or 5 ng/ml (grey bars)
(black bars, untreated); n = 4–5. (b) Gene expression of Il1b/IL1B, Ccl2/
CCL2 and TNFA in mouse and human islets after treatment with 1 ng/ml
eNAMPT monomer (grey bars) (black bars, untreated); n = 4–5. (c)
Mouse islets were treated with 5 ng/ml eNAMPT-WT or 1 ng/ml
eNAMPT monomer in combination with inhibitors of P38-MAPK
(SB203580; 1 μmol/l; purple bars), STAT3 (NCS74859; 50 μmol/l; grey
bars), JNK (SP600125; 50 μmol/l; blue bars) or NF-κB (BAY 11–7082;
1 μmol/l; brown bars) for 48 h (no inhibitor, black bars), and insulin
secretion was measured after static incubation with 2 mmol/l or
20 mmol/l glucose (n = 8–10). In (a–c), an n of 1 equals 150–250 islets.
Data are expressed asmeans ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001,
as indicated. In (c): †p < 0.05 for islets treated with JNK inhibitor and
5 ng/ml eNAMPT-WT vs islets treated with JNK inhibitor without
eNAMPT; ‡‡p < 0.01 for islets treated with JNK inhibitor and 1 ng/ml
eNAMPT monomer vs islets treated with JNK inhibitor without
eNAMPT. Data analysed by two-way ANOVAwith Sidak’s post hoc test
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0.05) but had no effects on the inhibitory actions of 5 ng/ml
eNAMPT-WT on GSIS (Fig. 5g). Thus, 1 ng/ml eNAMPT
induces NAD biosynthesis and requires islet NMN uptake to
exert its functional effects. In contrast, the effects of 5 ng/ml
eNAMPT were unaffected by inhibition of NMN uptake,
suggesting an NAD-independent pathway for these effects.
These data provide evidence that the bimodal effects of
eNAMPT-WT are related to loss of NAD-biosynthetic capac-
ity of eNAMPT at higher concentrations.
Discussion
This study demonstrates that eNAMPT exerts bimodal,
concentration- and structure-functional-dependent effects on
pancreatic beta cell functional mass, and provides clarification
of previous contradictory eNAMPT studies.
Low, physiological levels of eNAMPT (1 ng/ml) enhance
beta cell health through NAD-dependent mechanisms. Since
islets are continually exposed to low eNAMPT concentrations
in healthy non-diabetic individuals, this indicates a role for low
eNAMPT concentrations in maintaining beta cell health. Beta
cell identity genes were increased at 1 ng/ml eNAMPT,
highlighting the potential importance of physiological levels of
eNAMPT in maintaining beta cells in the fully differentiated
state. This is consistent with studies showing beta cell de-
differentiation following 3-day culture in the absence of circulat-
ing factors, including eNAMPT/NMN [41]. The effects of
1 ng/ml eNAMPTare mediated via NAD biosynthesis, suggest-
ing eNAMPTexists in the dimeric form at lower concentrations.
This is consistent with our observations in non-diabetic human
and mouse serum samples, which show eNAMPT dimer as the
predominant structural form of eNAMPT at low physiological
concentrations [12]. Whether eNAMPT can exert NAD biosyn-
thesiswithin the extracellular space remains controversial.Whilst
RPMI media contains sufficient nicotinamide to support
eNAMPT enzymatic activity, we were unable to detect
eNAMPT within spent islet media after eNAMPT incubation,
suggesting that at least some eNAMPT dimer is taken up into
the islet/beta cell, after which NMN synthesis occurs
intracellularly.
Mechanistically, eNAMPT-mediated NAD synthesis may
improve beta cell health through activation of NAD-dependent
sirtuins or via actions of NAD metabolites cyclic ADP-ribose
(cADPR) and nicotinic acid adenine dinucleotide phosphate
(NAADP), which reportedly induce intracellular calcium
mobilisation [13, 14, 16, 19].
Conversely, as eNAMPT concentrations rise to pathophysio-
logical levels, as in type 2 diabetes, eNAMPT induces islet
inflammation, and initiates beta cell dysfunction, beta cell death
and reduced beta cell mass and identity. Themechanisms driving
reduced beta cell number and identity are unclear. We have
demonstrated that high concentrations of eNAMPTenhance beta
cell apoptosis, however beta to alpha cell trans-differentiation or
beta cell de-differentiation may also play a role, and further stud-
ies are required to identify the precise mechanisms.
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Fig. 5 Structure-functional changes mediate the bimodal effects of
eNAMPT-WT. (a–d) MIN6 cells were incubated with either NMN
(100 μmol/l) or eNAMPT-WT (1 or 5 ng/ml) for 48 h. (a, b) intracellular
NMN and (c, d) intracellular NAD. In (a–d), n = 5–10, where n of 1
equals 1 well of a 12-well plate. (e, f) Mouse islets were treated with
NMN (100 μmol/l), and (e) static insulin secretion in response to
2 mmol/l glucose (black bars) or 20 mmol/l glucose (grey bars) was
analysed (n = 5–28, where an n of 1 equals five islets per incubation tube,
repeated 8–10 times) and (f) gene expression of Pdx1, Ins2 and Nkx2-2
was measured by quantitative RT-PCR (n = 5–12, where an n of 1 equals
RNA extracted from 150–200 islets). (g) Mouse islets were treated for
48 h with eNAMPT-WT (0.5, 1 or 5 ng/ml) in combination with the
CD73 inhibitor AMP-CP (1 μmol/l) and static insulin secretion was
measured in response to 20 mmol/l glucose (n = 17, where an n of 1
equals five islets per incubation tube, repeated 8–10 times). In (f) and
(g): black bars, 0 μmol/l NMN; grey bars, 100 μmol/l NMN. Data are
expressed as means ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs
untreated cells (in (b) and (d), untreated cells are at 0%) or as indicated,
by one-way ANOVA with Bonferroni’s post hoc test (a–d) or two-way
ANOVAwith Sidak’s post hoc test (e–g). U, untreated
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eNAMPT exerts beta cell dysfunction through NAD-
independent mechanisms, suggesting a switch towardmonomer-
ic eNAMPT at higher concentrations. This is consistent with
observations that the eNAMPT monomer was present at 1–
2 ng/ml in serum from individuals with type 2 diabetes, but
almost absent in serum from individuals without diabetes. It is
also consistent with our observations that increasing serum
eNAMPT did not correlate with increasing serum NMN.
Whilst elevated eNAMPT strongly correlated with increased
HbA1c, we did not observe notable correlations between
eNAMPT and BMI, and only a weak correlation between
eNAMPT and serum insulin. We hypothesise that, as glucose
rises during glucose intolerance, secretion of eNAMPT dimer
increases, which promotes islet compensation. However, as
eNAMPT levels continue to rise in response to elevated glucose,
eNAMPT dimer begins to break apart into constituent eNAMPT
monomers, which then drive beta cell failure. Thus, increases in
eNAMPT strongly correlate with increases in blood glucose and
HbA1c and do not necessarily precede hyperglycaemia. Precisely
why eNAMPT preferentially exists as a monomer at high levels
remains unclear but may relate to ligand-induced dimerisation,
whereby eNAMPT is stabilised andmaintained in dimer form by
the presence of an endogenous ligand.We hypothesise that insuf-
ficient concentrations of the putative ligand at higher eNAMPT
concentrations lead to break up of the dimer into constitutive
monomers.
Mechanistically, eNAMPT promoted islet inflammation
and beta cell failure through P38-MAPK and STAT3 path-
ways. Similar eNAMPT effects are reported in macrophages,
monocytes and islets of mice fed a high-fat diet (HFD) [7, 9,
12, 42]. Upstream, these effects may be receptor-mediated,
with eNAMPT reported to function via Toll-like receptor 4
(TLR4) [43], C-C chemokine receptor type 5 (CCR5) [44],
IGF and insulin receptor [8] signalling, although these remain
unconfirmed. Separately, the deleterious effects of eNAMPT
monomer may also reflect decreased eNAMPT dimer-
mediatedNAD synthesis, occurring independently from direct
effects of eNAMPT monomer.
Together, our results characterise structure-functional rela-
tionships as being of crucial importance to the effects of
eNAMPT on beta cell health. Moreover, we demonstrate a
novel mechanism of beta cell dysfunction in type 2 diabetes.
Strategies to block the actions of the eNAMPT monomer by
promoting dimerisation or stabilising eNAMPT in dimer form
could represent promising therapeutic approaches for the
treatment of diabetes.
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